$SFIX

Bacos Anthony sold $265K of SFIX

Bacos Anthony (Chief Prod/Technology Officer) sold 70,000 shares of Stitch Fix, Inc. (SFIX) at an average of $3.79 ($3.79–$3.79, $0.27M total) across 2 trades on 2026-07-20 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bacos Anthony
Published Jul 21, 2026, 8:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 21, 2026, 8:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SFIX
Neutral
medium confidence
Mentioned
$SFIX
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SFIXNeutralLow
01

Why it matters

The newest disclosed fact is the specific open-market sale of 70,000 shares by the Chief Product/Technology Officer on 2026-07-20, totaling $265,080, under a 10b5-1 plan.

02

Market read

Primarily a sentiment/positioning datapoint; no new operating or financial information is disclosed.

03

What to watch

Traders may over-weight insider sales; without accompanying changes in guidance, contracts, or operating metrics, the filing mainly informs positioning rather than valuation.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-21 after-hours, covering sales executed 2026-07-20.

Background

The article is an SEC Form 4 insider transaction disclosure for Stitch Fix, Inc. (SFIX).

Company-level read

Ticker impact

$SFIXNeutralMedium confidence
Context

Stitch Fix insider Bacos Anthony sold 70,000 shares in open-market trades on 2026-07-20 under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary sales. The disclosed sale size is moderate relative to a large-cap context, and no new fundamentals are provided.

Market effects

Minimal, as this is company-specific insider trading with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than a view on Stitch Fix fundamentals.

Key entities

  • Stitch Fix, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Bacos Anthony

    Chief Product/Technology Officer who executed the sale.

  • 10b5-1 plan

    Pre-arranged plan that typically reduces interpretive value of insider sales.

Related articles

$SFIXMedAI 8/10

Why Stitch Fix Stock Surged Today

Stitch Fix shares rose 15.69% on Thursday after the company reported fiscal 2026 Q3 results that beat investor expectations. Revenue increased 4.7% to $340 million; net revenue per active client rose 6.6% to $578. Net loss narrowed to $1.5 million, free cash flow was $6.5 million, and adjusted EBITDA rose 20% to $13.2 million. Stitch Fix raised full-year guidance to about $1.35 billion revenue and $49–$52 million adjusted EBITDA, with positive free cash flow.

$ORCLMedAI 8/10

Futures Rise, Oil Drops As US Ends Iran Strikes

US equity futures rose as tech and small caps gained after US Central Command said strikes against Iran were complete, easing concerns about further escalation and the Strait of Hormuz reopening. S&P futures rose 0.7% and Nasdaq 100 1.1%; bond yields fell 1–3bp. Brent slipped ~1% below $92; WTI fell to $88.87. Oracle shares fell ~8% after higher-than-estimated capex; Navan jumped 19% after raising revenue outlook.